Rashad Nawfal, MD
@RashadNawfal
Followers
258
Following
3K
Statuses
169
Postdoctoral Fellow @DanaFarber #FreedmanLab | MD '23 @LebaneseUni | Mia San Mia ⚽️🔴
Boston, MA
Joined June 2016
1) Excited to share our work @TheLancetOncol on the landscape of subsequent therapies in perioperative IO trials across cancer types. Effort co-led with @KarlSemaan with great mentorship from @peters_solange @tompowles1 @DrChoueiri and co-authors! Link:
6
16
63
RT @ConquerCancerFd: We are pleased to announce the recipients of 2025 Genitourinary Cancers Symposium Merit Awards to recognize first auth…
0
7
0
RT @DanaFarber_GU: Congratulations to GU Postdoctoral Fellows Marc Machaalani (@MarcMachaalani), Rashad Nawfal (@RashadNawfal), Clara Stein…
0
12
0
RT @ReneeSaliby: 1/ 🧵Excited to share our latest study published in @NatureCancer co-led with amazing co-first authors and friends @TJammih…
0
61
0
RT @DrChoueiri: 1/ Results from #LITESPARK-003 cohort 1 (1st Line) are out @TheLancetOncol! This phase II trial examined HIF2 inh Belzutifa…
0
40
0
RT @aadel_chaudhuri: Fantastic @CCR_AACR Translations piece from @jberchuck & colleagues on our recent @CCR_AACR paper uncovering a stemnes…
0
4
0
RT @TheLancetOncol: New in Perspectives: Essay: Landscape of subsequent therapies in perioperative #immunotherapy trials across multiple…
0
4
0
RT @DrChoueiri: SUPP FIG 2 tells it all---an example we worked on taking #KYN564 as an example. Subsequent therapies can be "many things" a…
0
17
0
2) We examined the landscape of subsequent therapies in perioperative immunotherapy trials, revealing key trends and unmet needs in adjuvant trials for melanoma, NSCLC, GEJ cancer, UC, and RCC. Tweetorial by superstar @KarlSemaan below:
1/ 🚨Happy to share our piece of work entitled “Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types”, just in @TheLancetOncol Effort co-led by @RashadNawfal with exceptional mentorship @peters_solange @tompowles1 @DrChoueiri
0
0
4
RT @KarlSemaan: 1/ 🚨Happy to share our piece of work entitled “Landscape of subsequent therapies in perioperative immunotherapy trials acro…
0
31
0
0
0
1
1
0
1
Here we go! After two years of great accomplishments at @DanaFarber_GU, the inimitable ⭐️ @KarlSemaan is applying to the #InternalMedicine #Match2025. Any program will be lucky to have him! @IMG_Oncologists #InsideTheMatch
Hello #MedTwitter #MedX! My name is Karl Semaan, #IMG from Lebanon @USJLiban, postdoctoral research fellow and computational epigenomics enthusiast @DanaFarber @harvardmed I am excited to be applying to #InternalMedicine for the #Match2025! AAMC ID: 16429630 #InsideTheMatch
1
0
9
Any program would be lucky to have @DanaFarber_GU superstar @eddy_saad! A dedicated and outstanding #InternalMedicine applicant! @IMG_Oncologists #InsideTheMatch
Hello #MedTwitter! I’m Eddy Saad, a @USJLiban graduate 🇱🇧 and currently a postdoc fellow studying kidney cancer and immunotherapy 🤓 @DanaFarber @harvardmed Incredibly grateful for the opportunity to be applying for the #InternalMedicine #Match2025 ! AAMC ID: 16349429 #IMG
1
0
9
RT @OncLive: 🎉Congrats rising star 🌟🌟🌟 @KarlSemaan , MD and post-doc from @DanaFarber_GU for his great poster at #ESMO24 🌟✨🌟 @yekeduz_emre…
0
6
0
RT @KarlSemaan: Great teams, great players, great company!⚽️🏆🎯 Thank you @cdanicas for outstanding organization as always #ESMO24 @myESMO…
0
6
0
RT @DrChoueiri: Outstanding talk from @Silke_Gillessen elegantly presenting PEACE-3 phase 3 trials first results. Adding 6 cycles of Ra22…
0
70
0
RT @DrChoueiri: New SOC for high-risk locally advanced cervical cancer (LACC)? The ph 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study shows that t…
0
21
0